Home/Filings/4/0001209191-21-025203
4//SEC Filing

Wesche Holger 4

Accession 0001209191-21-025203

CIK 0001708493other

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 5:00 PM ET

Size

15.4 KB

Accession

0001209191-21-025203

Insider Transaction Report

Form 4
Period: 2021-04-01
Wesche Holger
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2021-04-01$0.60/sh+1,534$92062,852 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-04-018,4662,540 total
    Exercise: $0.60Exp: 2027-01-13Common Stock (8,466 underlying)
  • Exercise/Conversion

    Common Stock

    2021-04-01$0.60/sh+8,466$5,08061,318 total
  • Sale

    Common Stock

    2021-04-01$21.14/sh500$10,57052,852 total
  • Sale

    Common Stock

    2021-04-01$20.41/sh9,500$193,92153,352 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    2021-04-011,53431,002 total
    Exercise: $0.60Exp: 2026-04-06Common Stock (1,534 underlying)
Footnotes (5)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  • [F2]Represents the weighted average sales price per share. The shares sold at prices ranging from $20.00 to $20.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  • [F3]Represents the weighted average sales price per share. The shares sold at prices ranging from $21.08 to $21.30 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  • [F4]The stock option vested and became exercisable as to 25% of the shares subject to the option on May 24, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the options are 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
  • [F5]The stock option vested and became exercisable as to 25% of the shares subject to the option on April 6, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Issuer

Harpoon Therapeutics, Inc.

CIK 0001708493

Entity typeother

Related Parties

1
  • filerCIK 0001763592

Filing Metadata

Form type
4
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 5:00 PM ET
Size
15.4 KB